Introduction/Background Platinum-resistant or -refractory ovarian cancer (PROC) confers a substantial symptom burden and cost. Health state utility values (HSUVs) provide summary measures of health-related quality of life (HRQoL) and are used in economic analyses. We aimed to comprehensively characterize HSUVs in PROC.

Methodology Two systematic literature reviews (SLRs) were conducted to characterize the economic burden and HRQoL in PROC recurring within 6 months of platinum-based chemotherapy. The original SLRs and SLR updates identified studies reporting HSUVs published between January 2010 and March 2, 2023, according to the recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. MEDLINE®, Embase®, EconLit, Cochrane, relevant conference proceedings, and health technology assessments were searched.

Results Overall, 13 studies reporting HSUVs in patients with PROC met the inclusion criteria. Among them, four were HRQoL studies and nine were economic analyses. The studies occurred in the United States (n=8), multiple countries (n=2), and the United Kingdom, Thailand, and Belgium (n=1 each). Reported HSUVs were heterogeneous, ranging from a high of 0.81 pre-progression to a low of 0.07 in hospitalized patients receiving end-of-life care. Mean HSUV for progressed PROC was 0.62 (n=7; range 0.40–0.78; figure 1). Among HSUVs reported with treatment regimens (range 0.56–0.84), paclitaxel or doxorubicin alone and vistusertib + paclitaxel had the lowest and highest values, respectively. Gastrointestinal perforation and bowel obstruction were associated with HSUVs of 0.50.

• Download figure
• Open in new tab
• Download powerpoint

Abstract #805 Figure 1

Reported utility values in patients with PROC

Conclusion Reported HSUVs within health states were heterogeneous; however, they declined following disease progression. Gastrointestinal complications and end-stage disease were associated with the lowest HSUVs. Well-tolerated treatments that extend progression-free survival are crucial in PROC.

Disclosures MI and MP are employees and shareholders of Novocure. ZC is employed under contract by Novocure.